LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

LLY

1,108.92

+3.86%↑

JNJ

206.8

+0.38%↑

ABBV

231.86

+1.03%↑

UNH

326.26

+2.45%↑

AZN

93.26

+1.86%↑

Home・Lista de Ações・Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc

Fechado

5.26 0.57

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

5.15

Máximo

5.34

Indicadores-chave
By Trading Economics
Rendimento	2.1M -7.7M
EPS	-0.13
Margem de lucro	-6,465.066
Funcionários	8
EBITDA	2.1M -7.1M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+74.8% upside

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	613K 315M
Abertura anterior	4.69
Fecho anterior	5.26

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

1.9 / 2.65 Suporte e Resistência

Aldeyra Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de abr. de 2025, 22:40 UTC

Grandes Movimentos do Mercado

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

Comparação entre Pares

Variação de preço

Aldeyra Therapeutics Inc Previsão

Preço-alvo

By TipRanks

74.8% parte superior

Previsão para 12 meses

Média 8.67 USD 74.8%

Máximo 10 USD

Mínimo 7 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Aldeyra Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

3 ratings

Comprar

Manter

Vender

Com base em 3 analistas que deram avaliações de ações para Aldeyra Therapeutics Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

1.9 / 2.65Suporte e Resistência

Recent bearish events outweigh bullish events.

All events are bearish.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.